Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

Betsy Goodfellow | May 22, 2024 | News story | Medical Communications |  Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab 

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active Crohn’s disease, with or without previous biologic failure, being treated with mirikizumab.

The trial demonstrated that treatment with the drug for this indication has a statistically significant and clinically meaningful improvement across multiple clinical and endoscopic endpoints throughout a year of treatment, compared to placebo. The drug met both co-primary endpoints and all major secondary endpoints at week 52 compared to placebo, including the proportion of participants achieving clinical response by patient reported outcomes (PRO) at week 12 and clinical remission at week 52.

In addition, the drug saw an improvement in the proportion of participants achieving a clinical response by PRO at week 12 and endoscopic response at week 52, compared to placebo.

Full data from the study was presented at Digestive Disease Week (DDW) in Washington DC, US, from 18-21 May 2024.

Mark Genovese MD, senior vice president of Eli Lilly’s immunology development, commented: “After one year of treatment, more than one-half of patients treated with mirikizumab achieved clinical remission and nearly one-half achieved endoscopic response. Remarkably, the majority of patients who achieved either of these endpoints, achieved both together. Lilly is committed to developing innovative treatments, like mirikizumab, that may improve upon the standard of care for people impacted by inflammatory bowel disease and immune-mediated diseases.”

Betsy Goodfellow